Zenith Drugs (NSE:ZENITHDRUG) Other Current Receivables: ₹129 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZENITHDRUG Zenith Drugs Ltd NSE:ZENITHDRUG
35 GF Score
Price ₹47.80
! 8 Warning Signs
View Full Analysis

What is Zenith Drugs Other Current Receivables?

Zenith Drugs NSE:ZENITHDRUG +4.03% 35 Other Current Receivables is ₹129 Mil as of Mar. 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 35/100. The stock has 8 warning signs investors should review.

Zenith Drugs's Other Current Receivables for the quarter that ended in Mar. 2026 was ₹129 Mil.

Zenith Drugs's quarterly Other Current Receivables increased from Mar. 2025 (₹2.18 Mil) to Sep. 2025 (₹137.45 Mil) but then stayed the same from Sep. 2025 (₹137.45 Mil) to Mar. 2026 (₹129.26 Mil).

Zenith Drugs's annual Other Current Receivables declined from Mar. 2024 (₹2.37 Mil) to Mar. 2025 (₹2.18 Mil) but then increased from Mar. 2025 (₹2.18 Mil) to Mar. 2026 (₹129.26 Mil).

Zenith Drugs Other Current Receivables Related Terms

Zenith Drugs Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Zenith Drugs's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs Other Current Receivables Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial 0.68 3.21 2.37 2.18 129.26

Zenith Drugs Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only 2.37 0.00 2.18 137.45 129.26
NSE:ZENITHDRUG
35GF Score
Zenith Drugs Ltd NSE:ZENITHDRUG
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenith Drugs Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹129 Mil mean?
Zenith Drugs (NSE:ZENITHDRUG) has a Other Current Receivables of ₹129 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Zenith Drugs and its competitors.
Is Zenith Drugs' Other Current Receivables too high?
Zenith Drugs' current Other Current Receivables is ₹129 Mil. Overall, Zenith Drugs has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Other Current Receivables compare to ZTS?
Zenith Drugs' Other Current Receivables of ₹129 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Zenith Drugs and its competitors. Zenith Drugs's current Other Current Receivables is ₹129 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Other Current Receivables of ₹129 Mil. The current Other Current Receivables is ₹129 Mil. Zenith Drugs' overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Other Current Receivables is ₹129 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenith Drugs Business Description

Address K. No. 72/5, Village Muradpura, Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
35GF Score

Get the complete analysis for NSE:ZENITHDRUG

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹47.80
Price